Leslie M. Randall, MD, associate professor, Division of Gynecologic Oncology, UC Irvine Health, discusses emerging treatment strategies in the treatment of patients with cervical cancer.
Leslie M. Randall, MD, associate professor, Division of Gynecologic Oncology, UC Irvine Health, discusses emerging treatment strategies for patients with cervical cancer.
The current management of patients with locally advanced cervical cancer is chemoradiation—this has been the standard of care for 20 years. Ongoing research is looking to improve this paradigm by bringing immunotherapy into the mix, Randall says.
In the metastatic setting, immunotherapy is being studied in several different ways. One approach is looking at cellular-based therapy through tumor infiltrating lymphocytes. Noncellular therapies on the rise include PD-1/PD-L1 and CTLA-4 inhibitors, as well as antibody-drug conjugates. Moreover, PARP inhibitors, which have transformed the ovarian cancer space, are also being studied in combination with immunotherapy and PIK3CA inhibition in cervical cancer, Randall says.